Search

Your search keyword '"Funazo, Tomoko"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Funazo, Tomoko" Remove constraint Author: "Funazo, Tomoko"
47 results on '"Funazo, Tomoko"'

Search Results

2. Supplementary Data S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer

3. Supplementary Figure S10 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer

4. Supplementary Table S6 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer

5. Data from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer

6. Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer

8. CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

9. Data from Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

10. Supplemental Legends from Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

11. Data File S1 from Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

12. Supplementary file 2 from Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

13. Data from Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

14. Supplementary materials from Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

15. Supplementary Data from Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

19. Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1 ‐rearranged lung cancer

20. Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series

21. Abstract 5335: Elucidation of initial resistance mechanisms in EGFR mutation-positive lung cancer focusing on YAP1 and cancer stem cells

22. Abstract 1601: CD47 related to intratumor heterogeneity in alectinib-resistant ALK-rearranged lung cancer cell lines

24. Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer.

26. Abstract 1098: Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

27. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade

29. Abstract 2728: Novel in vivo imaging method to evaluate “Don't eat me” signal of tumor against microglia

30. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

31. Abstract 72: YAP1 mediates initial survival of alectinib therapy in ALK-rearranged lung cancer via pro-apoptotic protein regulation

32. Abstract 1271: ABCC11 is involved in resistance to alectinib

33. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

37. Abstract 1830: A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer

38. Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

41. Successful oral desensitization with crizotinib after crizotinib‑induced hepatitis in an anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancer patient: A case report

42. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer

43. Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer

44. Varicella Reinfection with Unilateral Varicella Pneumonia

46. Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.

47. EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

Catalog

Books, media, physical & digital resources